Neuroendocrinology News

The way endocrinologists manage prolactinomas is changing.

More than half of adults with acromegaly receiving a novel once-daily oral medication achieved an insulin-like growth factor-1 level at or below the upper limit of normal, according to topline results from the PATHFNDR-2 trial.

Adults who achieved remission after surgery for Cushing’s disease are more likely to develop autoimmune disease than those with nonfunctioning pituitary adenomas, according to data published in Annals of Internal Medicine.

Hypercortisolism is prevalent among nearly one-quarter of people with difficult-to-control type 2 diabetes enrolled in a prospective phase 4 study, according to an industry press release.

Common data elements are needed to reduce heterogeneity in studies on transsphenoidal pituitary adenoma surgery, according to a systematic review published in Pituitary.

The FDA granted breakthrough therapy designation for an oral non-glucocorticoid medication for the treatment of congenital adrenal hyperplasia, according to an industry press release.

The addition of a radioligand therapy to first-line treatment with long-acting octreotide prolonged PFS for patients with gastroenteropancreatic neuroendocrine tumors, according to the agent’s manufacturer.

Adults with congenital adrenal hyperplasia receiving an oral corticotropin-releasing factor type 1 receptor antagonist had a greater reduction in daily glucocorticoid dose at 24 weeks than placebo, according to top-line phase 3 trial data.

More than 80% of adults with acromegaly achieved an insulin-like growth factor level at or below the upper limit of normal at 36 weeks with an investigational once-daily oral medication, according to topline results from a phase 3 trial.

Adults with endogenous Cushing’s syndrome reported that the condition moderately affects their quality of life and causes them to have symptoms about 16 days in a given month, according to findings published in Pituitary.